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Abstract. 
 
The survival motor neuron (SMN) protein, the
protein product of the spinal muscular atrophy (SMA)
disease gene, plays a role in the assembly and regenera-
tion of small nuclear ribonucleoproteins (snRNPs) and
spliceosomes. By nanoelectrospray mass spectrometry,
we identiﬁed RNA helicase A (RHA) as an SMN com-
plex–associated protein. RHA is a DEAH box RNA heli-
case which binds RNA polymerase II (pol II) and report-
edly functions in transcription. SMN interacts with RHA
in vitro, and this interaction is impaired in mutant SMNs
found in SMA patients. Coimmunoprecipitation demon-
strated that the SMN complex is associated with pol II,
snRNPs, and RHA in vivo. In vitro experiments suggest
that RHA mediates the association of SMN with the
COOH-terminal domain of pol II. Moreover, transfec-
tion of cells with a dominant negative mutant of SMN,
 
SMN
 
D
 
N27, causes accumulation of pol II, snRNPs, and
RHA in nuclear structures that contain the known mark-
ers of gems and coiled bodies, and inhibits RNA pol I and
pol II transcription in vivo. These ﬁndings indicate a func-
tional as well as physical association of the SMN complex
with pol II and suggest a role for the SMN complex in the
assembly of the pol II transcription/processing machinery.
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Introduction
 
Spinal muscular atrophy (SMA)
 
1
 
 is an autosomal recessive
disease and the most common genetic cause of infant
death (Pearn, 1980). SMA is characterized by degenera-
tion of motor neurons in the anterior horn of the spinal
cord, resulting in muscular weakness and atrophy (for re-
view see Melki, 1997). The survival motor neuron (SMN)
gene is the SMA determining gene (Lefebvre et al., 1995).
In humans, the SMN gene is duplicated as an inverted re-
peat on chromosome 5, and only deletions or mutations in
the telomeric copy, SMN1, result in SMA (for review see
Burghes, 1997). The centromeric copy, SMN2, does not
protect from SMA because, as a result of a single nucle-
otide difference from SMN1, it produces mostly a non-
functional truncated form of SMN lacking the COOH-ter-
minal amino acids encoded by exon 7 (Lefebvre et al.,
1995; Lorson et al., 1998, 1999; Pellizzoni et al., 1998, 1999;
Charroux et al., 2000). SMN is expressed in all tissues of
mammalian organisms, and its function is essential in hu-
mans, mice, 
 
Caenorhabditis elegans
 
, and 
 
Schizosaccharo-
myces pombe
 
 (Schrank et al., 1997; Miguel-Aliaga et al.,
1999; Hannus et al., 2000; Owen et al., 2000; Paushkin et
al., 2000). The amount of full length SMN produced by
SMN2 is sufficient to overcome lethality in most cells but
not in motor neurons where the amount of SMN inversely
correlates with the severity of the disease (Coovert et al.,
1997; Lefebvre et al., 1997; Frugier et al., 2000; Hsieh-Li et
al., 2000; Jablonka et al., 2000; Monani et al., 2000). There-
fore, motor neurons appear significantly more sensitive to
SMN reduction than other cell types.
SMN localizes both in the cytoplasm and in gems, nuclear
bodies similar in size and number to coiled bodies and often
associated with them (Liu and Dreyfuss, 1996). Recently, it
has been suggested that coiled bodies be renamed as Cajal
bodies (Gall et al., 1999). SMN is tightly associated with
Gemin2 (formerly SIP1), Gemin3, and Gemin4 as part of a
large multiprotein complex (Liu et al., 1997; Charroux et al.,
1999, 2000). In the cytoplasm, the SMN complex is also as-
 
sociated with the Smith antigen (Sm) core proteins of
snRNPs, suggesting a function in some aspects of snRNP
metabolism (Liu et al., 1997; Charroux et al., 1999, 2000).
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The pathway of spliceosomal snRNP assembly and function
in higher eukaryotes requires a cytoplasmic phase where the
snRNAs are exported from the nucleus, bind a common set
of proteins to form the Sm core and, after 5
 
9
 
 cap hyper-
methylation and 3
 
9
 
 end maturation, are imported into the nu-
cleus where snRNPs function in pre-mRNA splicing (Mat-
taj and De Robertis, 1985; Mattaj, 1986; Luhrmann et al.,
1990). Experiments in 
 
Xenopus laevis
 
 oocytes and in mam-
malian cells have demonstrated a key function for the SMN
complex in the cytoplasmic assembly of snRNPs (Fischer et
al., 1997; Pellizzoni et al., 1998; Buhler et al., 1999). In addi-
tion, SMN functions in the nucleus in pre-mRNA splicing, a
function which likely involves the regeneration of splicing
components after rounds of splicing (Pellizzoni et al., 1998;
Meister et al., 2000). SMN forms large oligomers, and this is
essential for its activity, since a defect in SMN oligomeriza-
tion correlates with SMA (Lorson et al., 1998; Pellizzoni et
al., 1999). SMN oligomerization is necessary for efficient in-
teraction with Sm proteins whereas SMN mutants found in
SMA patients are deficient in both splicing regeneration ac-
tivity and interaction with Sm proteins and with Gemin3
(Pellizzoni et al., 1998, 1999; Charroux et al., 1999; Friesen
and Dreyfuss, 2000).
Here, we report the identification by nanoelectrospray
mass spectrometry of RNA helicase A (RHA) as an SMN
complex-interacting protein. In vitro, SMN interacts with
RHA and this interaction is impaired for SMN mutants
found in SMA patients. In vivo, the SMN complex is associ-
ated with RNA polymerase II (pol II), snRNPs, and RHA
in a large complex. In the nucleus, the COOH-terminal do-
main (CTD) of pol II physically and functionally couples
transcription, splicing, and polyadenylation (Steinmetz,
1997). We show that the SMN complex interacts with pol II
CTD and this association is mediated, at least in part, by
RHA. Expression of a dominant negative mutant of SMN
(SMN
 
D
 
N27) causes a dramatic reorganization of spliceoso-
mal snRNPs into large nuclear accumulations which con-
tain gem- and coiled body–specific markers (Pellizzoni et
al., 1998). We show that expression of SMN
 
D
 
N27 also
causes the specific accumulation of the hypophosphory-
lated form of pol II (pol IIa) and RHA in these structures
and inhibits transcription in vivo. Our findings suggest a
role for the SMN complex in transcription, possibly for as-
sembly of the key components of the mRNA transcription/
processing machinery before their association with genes.
 
Materials and Methods
 
DNA Constructs
 
The cDNA encoding SMN was described previously (Liu and Dreyfuss,
1996). Plasmids expressing myc-tagged SMN wild-type and SMN
 
D
 
N27
proteins under the control of the cytomegalovirus promoter were de-
scribed previously (Pellizzoni et al., 1998). The RHA cDNA was a kind
gift of Dr. Chee-Gun Lee (UMDNJ, New Jersey Medical School, Newark,
NJ; Lee and Hurwitz, 1993).
 
Antibodies
 
Antibodies used in these experiments were as follows: mouse IgG1 mono-
clonal anti-SMN (2B1; Liu and Dreyfuss, 1996); mouse IgG1 monoclonal
anti-Gemin2 (2E17; Liu et al., 1997); mouse IgG1 monoclonal anti-Gemin3
(11G9; Charroux et al., 1999); mouse IgG1 monoclonal anti-Gemin4
(22C10; Charroux et al., 2000); mouse IgG1 monoclonal antibromouridine
(BrU) (Sigma-Aldrich); mouse IgG1 monoclonal anti-SC35 (Fu and Mani-
atis, 1990); mouse IgG3 monoclonal anti-Sm (Y12, Lerner et al., 1981);
mouse IgG1 monoclonal anti-myc (9E10); affinity-purified rabbit polyse-
 
rum anti-myc 9E10 epitope (A-14; Santa Cruz Biotechnology, Inc.);
 
 
 
mouse
IgM monoclonal anti-pol IIo (H5; Bregman et al., 1995; BabCo); mouse
IgG2a monoclonal anti-pol IIa (8WG16; Thompson et al., 1989; BabCo);
mouse IgG2a monoclonal anti-heterogeneous (hn)RNPA1 (4B10; Pinol-
Roma et al., 1988); mouse IgG2b monoclonal anti-hnRNPC1/C2 (2B12;
Dreyfuss et al., 1984); mouse IgG1 monoclonal anti-U2B
 
99
 
 (4G3; Habets et
al., 1989; Cappel); mouse IgG2a monoclonal anti-TFIIB (Transduction lab-
oratories); rabbit polyserum anti–TATA box binding protein (TBP; Kato
et al., 1994); and rabbit polyserum anti-RHA (Nakajima et al., 1997).
 
Cell Culture and Treatments
 
HeLa cells were cultured in DME (GIBCO BRL) supplemented with
10% FBS (GIBCO BRL). HeLa cells, plated on glass coverslips, were
transfected by the standard calcium phosphate method. After overnight
incubation with DNA, cells were washed and fresh medium was added.
Transfected cells were fixed and processed by immunofluorescence stain-
ing after an additional 24–36
 
 
 
h of incubation. Transfection efficiencies of
myc-SMN wild-type and myc-SMN
 
D
 
N27 plasmids were similar. Western
blot analysis of lysates from transfected cells showed single bands of the
expected size corresponding to myc-SMN wild-type and myc-SMN
 
D
 
N27
proteins, the expression level of both proteins was approximately 10-fold
over the endogenous SMN level (data not shown).
For in situ detection of sites of transcription, HeLa cells grown on glass
coverslips were incubated for 1 h in culture medium containing 2 mM BrU
(Sigma-Aldrich), washed briefly three times with PBS, fixed, and pro-
cessed by immunofluorescence staining with anti-BrU monoclonal anti-
bodies. RNase and DNase treatments were performed before immunoflu-
orescence staining at room temperature in PBS containing 200 
 
m
 
g/ml
RNase A and 100 
 
m
 
g/ml DNase I, respectively. To inhibit pol I or both pol
I and pol II, HeLa cells were incubated for 3 h in the presence of either
0.04 or 5 
 
m
 
g/ml actinomycin D, respectively, before addition of BrU. To
inhibit pol II activity, 
 
a
 
-amanitin (50 
 
m
 
g/ml) was added to the culture me-
dium 4 h before the addition of BrU.
 
Immunofluorescence Microscopy
 
Cells grown on glass coverslips were briefly washed with PBS, fixed in 2%
formaldehyde PBS for 20 min at room temperature, permeabilized either in
acetone for 3 min at 
 
2
 
20
 
8
 
C or in 0.5% Triton X-100 PBS for 5 min at room
temperature. Cells were blocked in PBS containing 3% BSA for 1 h at
room temperature. Double-label immunofluorescence experiments were
performed by separate sequential incubations of each primary antibody fol-
lowed by incubation with its specific secondary antibody coupled to FITC
or Texas red diluted in PBS–3% BSA. All incubations were at room tem-
perature for 1 h. Laser confocal fluorescence microscopy was performed
with a Leica TCS four-dimensional (Germany) confocal microscope. Im-
ages from each channel were recorded separately and then merged.
 
Immunoprecipitation Experiments
 
Immunoprecipitations were carried out using HeLa cell nucleoplasmic ex-
tract prepared in the presence of 0.5% Triton X-100 as described previ-
ously (Pinol-Roma et al., 1988). Immunoblotting was performed as de-
scribed previously (Liu et al., 1997).
 
Protein Microsequencing by Mass Spectrometry
 
The p130 protein was coimmunoprecipitated from total HeLa cell extract
with anti-Gemin3 monoclonal antibody (11G9), and the band was excised
from a single one-dimensional Coomassie-stained polyacrylamide gel and
in gel digested with trypsin as described previously (Shevchenko et al.,
1996). Tryptic peptides were recovered from gel pieces by extraction with
5% formic acid and acetonitrile. The combined extracts were pooled,
dried in a speed vac, and peptides were sequenced by nanoelectrospray
tandem mass spectrometry (nano-ES MS/MS) as described in Wilm et al.
(1996). The sequencing was performed on a PE-Sciex QSTAR instrument
equipped with an ion source from Protana. Comprehensive protein and
EST databases were searched using the Protana Software suite. No limita-
tions on protein molecular weight and species of origin were imposed.
 
Recombinant Proteins Production
 
His-tagged SMN wild-type and mutant proteins cloned into pET28 and
the glutathione 
 
S
 
-transferase (GST) fusion of SMN and Gemin2 cloned
into pGEX-5X were described previously (Pellizzoni et al., 1998, 1999). A
GST–Gemin2 fusion construct, containing a tobacco etch virus protease
cleavage site NH
 
2 
 
terminal of Gemin2, in a pET21 vector carrying the 
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p15A origin of replication was kindly provided by Dr. Greg Van Duyne
(University of Pennsylvania, Philadelphia, PA). GST–Gemin2 and his-
tagged SMN wild-type or mutant proteins were coexpressed by cotrans-
formation of the respective plasmids into 
 
Escherichia coli
 
 BL21(DE3) fol-
lowed by induction with 1 mM IPTG at 17
 
8
 
C for 15 h. The recombinant
proteins were purified by affinity chromatography on glutathione-
Sepharose beads (Pharmacia) according to the manufacturer’s instruc-
tions. The plasmid encoding the GST–CTD fusion protein was a generous
gift of Dr. James Manley (Department of Biological Sciences, Columbia
University, New York, NY). GST–CTD was produced in 
 
E. coli
 
BL21(DE3) and purified as described above.
 
In Vitro Protein-binding Assay
 
The RHA full length (1–1279) and the RHA
 
D
 
RGG COOH-terminal de-
letion (1–1106) proteins were produced by in vitro–coupled transcription/
translation (Promega) in the presence of [
 
35
 
S]methionine (Amersham
Pharmacia Biotech) using the RHA cDNA,
 
 
 
either undigested or digested
with Bgl II, respectively. Purified GST, GST–Gemin2, or GST–Gemin2/
SMN proteins (2 
 
m
 
g) bound to 25 
 
m
 
l of glutathione-Sepharose beads were
incubated with in vitro–translated protein products in 1 ml of binding
buffer (50 mM, Tris-HCl, pH 7.5), 200 mM NaCl, 2 mM EDTA, 0.1% NP-
40, 2 
 
m
 
g/ml leupeptin, pepstatin A, and aprotinin). After incubation for
1 h at 4
 
8
 
C, the beads were pelleted, washed five times with 1 ml of binding
buffer, and boiled in SDS-PAGE sample buffer. The eluted proteins were
analyzed by SDS-PAGE, and the signal was enhanced by treatment with
Amplify solution (Amersham Pharmacia Biotech). Purified GST or GST–
CTD bound to glutathione-Sepharose beads was incubated with either
HeLa nuclear extract prepared according to Dignam et al. (1983), or
[
 
35
 
S]methionine-labeled in vitro–translated proteins in buffer D contain-
ing 0.025% NP-40 at 4
 
8
 
C. After five washes with the same buffer, bound
proteins were eluted by boiling in SDS-PAGE, sample buffer, separated
by SDS-PAGE and analyzed by Western blotting or autoradiography.
 
Results
 
Identification of RHA as an SMN-interacting Protein
 
We have recently identified two novel components of the
SMN complex by a combination of coimmunoprecipitation
and mass spectrometry (Charroux et al., 1999, 2000). Im-
munoprecipitations from [
 
35
 
S]methionine-labeled HeLa
cell lysates with antibodies against components of the
 
SMN complex revealed the presence of additional proteins
whose identity is not yet known (Liu et al., 1997; Charroux
et al., 1999, 2000). Here, we employed the same strategy to
identify a novel SMN complex-interacting protein. Fig. 1 A
shows the proteins that specifically coimmunopurify with
anti-Gemin3 antibodies compared with antitransportin
antibodies as a control. In addition to the known compo-
nents of the SMN complex (SMN, Gemin2, Gemin3, and
Gemin4), there are protein bands of 
 
z
 
175, 130, and 95 kD.
These bands were excised from the gel and digested with
trypsin. The resulting peptides were sequenced by nano-
electrospray mass spectrometry as described in Materials
and Methods. In this paper, we report the identification of
the 130-kD protein and experiments that led us to propose
a role for the SMN complex in transcription. Databases
search with several peptides revealed that p130 is identical
to RHA, an essential ATP-dependent RNA helicase of the
DEAH family (Lee and Hurwitz, 1993; Lee et al., 1998).
Because RHA contains an RGG box at the COOH ter-
minus and SMN has been found to interact with some argi-
nine- and glycine-rich domains (Liu and Dreyfuss, 1996;
Friesen and Dreyfuss, 2000), we tested whether RHA can
bind SMN in vitro. Fig. 1 B shows that in vitro–translated
RHA binds efficiently to purified recombinant GST–SMN
but not to GST–Gemin2 or GST alone. We also tested the
ability of SMN mutants, expressed and purified as GST–
Gemin2/SMN complexes, to bind RHA in vitro (Fig. 1 C).
SMN interaction with RHA is impaired by either a single
point mutation (SMNY272C) or a deletion of the amino
acids encoded by exon 7 (SMN
 
D
 
Ex7) as found in some
SMA patients. In contrast, the binding of SMN
 
D
 
N27 to
RHA is indistinguishable from that of SMN wild-type.
Furthermore, the RGG-rich COOH-terminal domain of
RHA, which is not required for its interactions with pol II
and with transcriptional coactivators (Nakajima et al.,
1997; Anderson et al., 1998), is necessary for interaction
with SMN (Fig. 1, C and D).
Figure 1. Identification of RHA as a novel SMN-
interacting protein. (A) Coimmunoprecipitation ex-
periments with anti-Gemin3 (11G9) or antitrans-
portin (19D9) monoclonal antibodies were carried
out from total HeLa cell extract. The immunopre-
cipitates (IP) were analyzed by SDS-PAGE and
Coomassie blue staining. The band corresponding
to the p130 protein coimmunoprecipitated with
anti-Gemin3 antibodies was excised and identified
by nanoelectrospray tandem mass spectrometry as
described in Materials and Methods. Molecular
weight markers, heavy (Ig h.c.) and light (Ig l.c.)
chains of immunoglobulins, and the bands corre-
sponding to the components of the SMN complex
are indicated. (B) SMN interacts with RHA in vitro.
In vitro–translated [35S]methionine-labeled RHA
full length (RHA) was incubated with either GST,
GST–Gemin2, or GST–SMN as indicated. 10% of
the input is shown. (C) The SMN interaction with
RHA is impaired by SMN mutations found in SMA
patients and requires the RGG-rich domain of
RHA. In vitro–translated [35S]methionine-labeled
RHA full-length (RHA) or a COOH terminus deletion lacking the RGG domain (RHADRGG) were incubated with the indicated
GST–Gemin2/SMN complexes containing either wild-type (wt) or mutant his-SMN proteins coexpressed and purified as described in
Materials and Methods. 10% of the input is shown. (D) Schematic representation of the structure of RHA and the domains involved in
the interaction with pol II, BRCA1, CBP, and SMN. 
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Association of the SMN Complex with Pol II, snRNPs, 
and RHA
 
We further examined the association between RHA and
the SMN complex in vivo by coimmunoprecipitation ex-
periments. Anti-RHA antibodies specifically coimmuno-
precipitate SMN, Gemin2, Gemin3, and Gemin4 in addi-
tion to snRNPs and both hyperphosphorylated (pol IIo)
and hypophosphorylated (pol IIa) pol II (Fig. 2). The gen-
eral transcription factors TBP and transcription factor IIB
are also detected in the RHA immunoprecipitate. None of
these proteins are detectable in immunoprecipitates using
a rabbit preimmune serum, and the abundant hnRNP A1
is not detected in the RHA immunoprecipitate. Fraction-
ation of an HeLa nuclear extract by sucrose gradient cen-
trifugation indicates that 
 
.
 
30% of nuclear SMN, Gemin2,
Gemin3, and Gemin4 cofractionate with RHA, snRNPs,
and pol II as a large complex (Paushkin, S., and G. Drey-
fuss, unpublished results). These results demonstrate
that a large nuclear complex exists which contains pol II,
snRNPs, RHA, and components of the SMN complex.
The CTD of pol II plays a key role in coupling transcrip-
tion and pre-mRNA processing by interacting directly
with components of the RNA processing machinery (for
review see Steinmetz, 1997). To ask if the SMN complex
can bind pol II CTD, we employed an approach similar to
the one used to demonstrate the physical interaction of
polyadenylation factors with pol II CTD (McCracken et
al., 1997). We investigated whether pol II CTD can associ-
ate with the SMN complex by pull-down experiments from
HeLa nuclear extract using GST–CTD. Fig. 3 A shows
that SMN, Gemin2, Gemin3, and Gemin4 specifically as-
sociate with pol II CTD. The interaction of the SMN com-
plex is not influenced by the phosphorylation state of the
CTD (data not shown).
RHA has been suggested to function in transcription as a
direct molecular link between pol II and transcriptional co-
activators including cAMP response element binding pro-
tein (CBP)/p300 and breast cancer gene 1 (BRCA1; Naka-
jima et al., 1997; Anderson et al., 1998). We addressed
the possibility that RHA may play a similar role in the as-
sociation of SMN with pol II CTD. To do so, we incu-
bated GST–CTD with in vitro–translated [
 
35
 
S]methionine-
labeled SMN in the presence or absence of similarly
produced RHA and found that RHA stimulates the bind-
ing of SMN to pol II CTD (Fig. 3 B). Although these inter-
actions may be mediated by additional components in the
reticulocyte lysate or in the nuclear extract, the data strongly
suggest that the SMN complex associates with pol II and
that RHA promotes this association possibly by stabilizing
or acting as a bridging factor between pol II CTD and SMN.
 
Pol IIa Accumulates in the G/CBs
 
Previous transfection experiments in HeLa cells with
SMN
 
D
 
N27 showed that this dominant negative SMN mu-
tant blocks snRNP assembly in the cytoplasm, causes a pro-
found rearrangement of snRNPs in the nucleus, and inhibits
pre-mRNA splicing in vitro (Pellizzoni et al., 1998). To ad-
dress further the possible involvement of the SMN complex
in transcription, we examined the subcellular localization of
pol II in cells expressing SMN
 
D
 
N27. Consistent with previ-
ous reports (Bregman et al., 1995), pol IIa shows a diffuse
nucleoplasmic punctate distribution excluding nucleoli, and
this is also the case in cells transfected with SMN wild-
type (Fig. 4, A–C). However, in cells transfected with
SMN
 
D
 
N27, pol IIa is reorganized and accumulates in large
nuclear aggregates which contain gem- and CB-specific
markers (G/CBs [Fig. 4, D–F]). For brevity, we shall refer to
these merged accumulations as G/CBs. The CTD of pol II
undergoes extensive phosphorylation in vivo and pol IIo
Figure 2. Association of the SMN
complex with RHA in vivo. Immu-
noprecipitation (IP) experiments
were carried out on HeLa cell nu-
cleoplasmic extract using anti-RHA
or control rabbit preimmune anti-
bodies. Immunoprecipitates were
analyzed by SDS-PAGE and West-
ern blotting with the antibodies to
the indicated proteins. 10% of the
input is shown.
Figure 3. The SMN complex interacts with pol II
CTD in vitro. (A) GST–CTD affinity chromatog-
raphy. HeLa nuclear extract was incubated with
either purified recombinant GST or GST–CTD,
and bound proteins were analyzed by SDS-PAGE
and Western blotting with antibodies to the indi-
cated proteins.  2.5% of the input is shown. (B)
RHA stimulates the interaction of SMN with pol
II CTD. In vitro–translated [35S]methionine-
labeled SMN, with (1) or without (2) in vitro–translated [35S]methionine-labeled RHA, was in-
cubated with purified recombinant GST–CTD or GST as indicated. Binding reactions contained
equal amounts of reticulocyte lysate. Bound proteins were analyzed by SDS-PAGE and autora-
diography. 1% of the input is shown. 
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Figure 4. Expression of
SMNDN27 causes accumula-
tion of pol IIa in G/CBs.
(A–F) Double-label confocal
immunofluorescence experi-
ments using anti-myc (A and
D), and anti-pol IIa (B and
E) antibodies on HeLa cells
transiently transfected with
mycSMNwt (A–C) and
mycSMNDN27 (D–F). (G–L)
Double-label confocal immu-
nofluorescence experiments
using anti-myc (G and J) and
anti-pol IIo (H and K) anti-
bodies on HeLa cells tran-
siently transfected with
mycSMNwt (G–I) and
mycSMNDN27 (J–L). The re-
spective combined images are
shown in C, F, I, and L. Colo-
calization results in a yellow
signal. Dashed lines demar-
cate the nucleus. Bars, 5 mm.
 
shows a speckled nucleoplasmic distribution more evident
by confocal than by standard epifluorescence microscopy
(Bregman et al., 1995; Zeng et al., 1997). The pattern of pol
IIo distribution in cells transfected with SMN wild type,
similar to untransfected cells, shows little or no localization
in gems (Fig. 4, G–I). Surprisingly, on transfection with
SMN
 
D
 
N27, pol IIo is excluded from the large G/CBs, the
diffuse nucleoplasmic pool appears reduced, and most of
pol IIo is localized in interchromatin granule clusters
(IGCs) around the G/CBs (Fig. 4, J–L; see Fig. 6, G–I).
 
RHA, TBP, and snRNPs Accumulate in the G/CBs
 
Next, we examined the effect of SMN
 
D
 
N27 expression on
the localization of RHA. RHA shows a nucleoplasmic dis-
tribution in untransfected HeLa cells and in cells trans-
fected with SMN wild-type and with no evident colocaliza-
tion with the G/CBs (Fig. 5, A–C). However, in cells
transfected with SMN
 
D
 
N27, RHA becomes relocalized in
the nucleus and accumulates in the large G/CBs (Fig. 5,
D–F). We also examined additional components of the pol
II transcription/processing machinery such as TBP, poly-
pyridimidine tract binding protein-associated splicing fac-
tor, and polyadenylation factors CstF64 and CPSF160, and
found them to be similarly reorganized (Fig. 5, G–I; and
data not shown). This reorganization of pol II, RHA,
and TBP is restricted to the nuclear SMN
 
D
 
N27-containing
aggregates, whereas Sm proteins of spliceosomal snRNPs
also accumulate in the cytoplasmic aggregates (Fig. 5, J–L),
consistent with a role of the SMN complex in cytoplas-
mic snRNP assembly (Pellizzoni et al., 1998). In summary, 
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several key components of the transcription and pre-
mRNA processing machineries are strongly affected by
SMN
 
D
 
N27 expression and accumulate in the G/CBs.
 
Specificity of the Accumulation of Transcription and 
Pre-mRNA Processing Components in G/CBs
 
To assess the specificity of the accumulation in G/CBs of
the components described above, we examined the effect
of SMN
 
D
 
N27 expression on hnRNP and serine- and argi-
nine-rich (SR) proteins, two classes of protein that are both
well characterized and intimately involved in the process
of mRNA biogenesis. HnRNP proteins are very abundant
nuclear RNA-binding proteins which interact with pre-
mRNAs as they emerge from the transcription complex,
modulate most of the posttranscriptional processes, and
accompany the spliced mRNA to the cytoplasm (Dreyfuss
et al., 1993). Fig. 6, A–F, shows that neither hnRNP A1
nor hnRNP C1/C2 proteins are reorganized by expression
of SMN
 
D
 
N27, and they are excluded from the G/CBs.
Similarly, the essential splicing factor SC35, which is also a
marker of IGCs (Spector, 1993), does not accumulate in
the G/CBs (Fig. 6, G–I). Staining with another monoclonal
antibody that reacts with the entire class of SR proteins
shows a similar exclusion (Zahler et al., 1992; data not
shown). Together these results demonstrate the specificity
of the relocalization of components to G/CBs observed by
expression of SMN
 
D
 
N27. Nevertheless, SMN
 
D
 
N27 ex-
pression alters the distribution of SC35. IGCs are found
closely associated with the periphery of G/CBs, lose inter-
Figure 5. Expression of
SMNDN27 causes accumula-
tion of RHA, TBP, and
snRNPs in G/CBs. (A–F)
Double-label  confocal immu-
nofluorescence experiments
using anti-myc (A and D) and
anti-RHA (B and E) antibod-
ies on HeLa cells transiently
transfected with mycSMNwt
(A–C) and mycSMNDN27
(D–F). (G–I) Double-label
confocal immunofluores-
cence experiments using anti-
myc (G) and anti-TBP (H)
antibodies on HeLa cells
transiently transfected with
mycSMNDN27. (J–L) Dou-
ble-label confocal immuno-
fluorescence experiments us-
ing anti-myc (J) and anti-Sm
(K) antibodies on HeLa cells
transiently transfected with
mycSMNDN27. The respec-
tive combined images are
shown in C, F, I, and L. Colo-
calization results in a yellow
signal. Dashed lines demar-
cate the nucleus. Bars, 5 mm. 
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connections with the surrounding nucleoplasm, and round
up their contour in a way that resembles what is observed
when transcription is inhibited by drugs or heat shock
(Figs. 4 and 6; Zeng et al., 1997).
 
Expression of SMN
 
D
 
N27 Inhibits Transcription In Vivo
 
Because of the strong effects of SMN
 
D
 
N27, we were inter-
ested to determine whether transcription of pre-mRNAs
in these cells is affected. The current methods for in situ
detection of nascent RNA transcripts rely on microinjec-
tion of BrU triphosphate into living cells or run-on tran-
scription in permeabilized cells followed by indirect immu-
nofluorescence microscopy (Jackson et al., 1993; Wansink
et al., 1993). By analogy with early experiments using
[
 
3
 
H]uridine incorporation for in vivo labeling of RNA (Fa-
kan and Bernhard, 1971), we developed a simple method
that avoids microinjection to detect transcriptional activity
in living cells in situ (Fig. 7). An in situ method was neces-
sary because only a fraction of the cells are transfected
with SMN
 
D
 
N27. We found that the addition of BrU to the
culture medium results in its efficient uptake and incorpo-
ration into nascent RNA by the cells. Fig. 7 A shows the
results of labeling HeLa cells for 1 h with 2 mM BrU fol-
lowed by cell fixation and staining with anti-BrU anti-
bodies. Pol II transcription sites are visible as anti-BrU
reactive dots scattered throughout the nucleoplasm. No-
ticeably, nucleolar labeling, which is not readily detected
by the methods of BrU triphosphate microinjection and
run-on transcription in permeabilized cells (Jackson et al.,
1993; Wansink et al., 1993), is also very intense. Higher
concentrations of BrU do not increase the intensity of the
signal but the intensity does increase proportional to the
time of incubation (data not shown). The sensitivity of
the staining to RNase treatment demonstrates that BrU
was incorporated into RNA (Fig. 7 B). Although BrU may
also be used as a thymidine analogue and become incorpo-
rated into DNA (Eidinoff et al., 1959), the staining we ob-
served is resistant to DNase digestion, demonstrating that
DNA incorporation does not significantly contribute to
the signal detected (Fig. 7 C). Treatment with low concen-
trations of actinomycin D selectively inhibits transcription
by pol I in the nucleolus (Fig. 7 D), whereas higher con-
centrations inhibit both pol I and pol II activities (Fig. 7
E). Extranucleolar incorporation is also strongly reduced
by treatment with 
 
a
 
-amanitin concentrations that inhibit
pol II (Fig. 7 F). This method is rapid, simple, sensitive,
and less invasive than previous methods, and is therefore
probably more reflective of physiological transcription.
Using this method, we examined the transcriptional activ-
ity of cells transfected with SMN wild type or SMN
 
D
 
N27.
Figure 6. Specificity of the
effects of SMNDN27 expres-
sion. (A–I) Double-label
confocal immunofluores-
cence experiments using
anti-myc (A, D, and G) and
either anti-hnRNP A1, anti-
hnRNP C1/C2 or anti-SC35
antibodies (B, E, and H, re-
spectively) on HeLa cells
transiently transfected with
mycSMNDN27. The respec-
tive combined images are
shown in C, F, and I. Dashed
lines demarcate the nucleus.
Bars, 5 mm. 
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Cells transfected with SMN wild-type, similar to untrans-
fected cells, show high levels of transcription both in the nu-
cleoplasm and in the nucleolus. No significant coincidence
between SMN (or gem) staining with the sites of transcrip-
tion was observed (Fig. 8, A–C). Strikingly, expression of
SMN
 
D
 
N27 strongly inhibits transcription both in the nucleo-
plasm and in the nucleolus, corresponding to pol II and pol
I activities, respectively (Fig. 8, D–F). A reduction in the
nucleoplasmic pool of pol II due to the accumulation of pol
II in the G/CBs provides a likely explanation for the inhibi-
tion of transcription upon expression of SMN
 
D
 
N27.
 
Discussion
 
We have identified RHA as a novel SMN-interacting pro-
tein and showed that this interaction is defective in SMN
mutants found in some SMA patients. Coimmunoprecipi-
tation and pull-down experiments demonstrated the physi-
cal association of the SMN complex with pol II, snRNPs,
and RHA in vivo and in vitro. Importantly, the SMN com-
plex binds pol II CTD, and RHA at least in part mediates
this interaction. Thus, RHA likely plays a role in the asso-
ciation between the SMN complex and pol II possibly simi-
lar, but not mutually exclusive, to its role in bridging CBP
and BRCA1 to pol II (Nakajima et al., 1997; Anderson et
 
al., 1998). We further demonstrated that expression of
SMN
 
D
 
N27 brings about a profound rearrangement of pol
II, RHA, snRNPs, TBP and polyadenylation factors, all of
which specifically accumulate in enlarged G/CBs. This re-
organization is accompanied by the inhibition of both pol I
and pol II transcription, as detected in vivo by the BrU la-
beling method we have developed. These findings indicate
a physical as well as a functional interaction between the
SMN complex and components of the pol II transcription/
processing machinery. Previous studies have indicated the
presence of additional proteins associated with the SMN
complex and the possibility that multiple SMN complexes
may exist in vivo (Liu et al., 1997; Charroux et al., 1999,
2000; Meister et al., 2000). The observations that RHA
does not localize to gems and is not found in all SMN com-
plexes suggest that RHA is not a core component of the
SMN complex such as Gemin2, Gemin3, and Gemin4. Sim-
ilar to Sm proteins of spliceosomal snRNPs, we consider
RHA as a possible substrate of SMN complex function.
The structure and organization of the nucleus are highly
dynamic (Lamond and Earnshaw, 1998; Misteli and Spec-
tor, 1998; Lewis and Tollervey, 2000). Actively transcrib-
ing genes are found throughout the nucleus, and pol II
transcriptional activity is not restricted to specific regions
Figure 7. A rapid method for the in situ detection of transcription. (A) Indirect immunofluorescence detection of nascent RNA by laser
confocal microscopy using anti-BrU antibodies on HeLa cells labeled in the presence 2 mM BrU as described in Materials and Methods.
(B) Effect of RNase A treatment before immunostaining. (C) Effect of DNase I treatment before immunostaining. (D–E) Effect of low
(0.04 mg/ml) or high (5 mg/ml) doses of actinomycin D (ActD) on BrU incorporation into RNA. (F) Effect of a-amanitin (50 mg/ml) on
BrU incorporation into RNA. Dashed lines demarcate the nucleus. Bars, 5 mm.Pellizzoni et al. A Role for SMN in Transcription 83
(Jackson et al., 1993; Wansink et al., 1993). Since the initial
observations of cotranscriptional splicing in vivo, consider-
able evidence has accumulated that most pre-mRNA pro-
cessing steps take place coordinately at sites of transcrip-
tion (Beyer and Osheim, 1988; Bauren and Wieslander,
1994). Physical and functional interactions between the
transcriptional apparatus and the capping, splicing and
polyadenylation machineries have recently been demon-
strated, and pol II appears to be a key factor in coordinat-
ing all the major pre-mRNA processing events through its
CTD (for review see Steinmetz, 1997; Neugebauer and
Roth, 1997; Corden and Patturajan, 1998; Bentley, 1999;
Hirose and Manley, 2000). Pol II CTD has been shown to
associate with the capping enzyme, snRNPs, splicing and
polyadenylation factors, possibly forming a large complex
for which the terms “mRNA factory” or “transcripto-
some” have been used (Halle and Meisterernst, 1996; Mc-
Cracken et al., 1997; Corden and Patturajan, 1998). Re-
cently, a role for CBs in the assembly of transcriptosomes
has been suggested (Gall et al., 1999).
Our findings are consistent with the possibility that the
assembly of transcriptosomes is a process that is extrinsic
to, and precedes, binding of the polymerase complex to
gene promoter elements. Most importantly, we propose
that the SMN complex plays a central role in the pathway
of transcriptosome assembly. The physical association of
the SMN complex with components of the pol II transcrip-
tion/processing machinery in untransfected cells indicates
that they interact under normal conditions, and expression
of SMNDN27 likely blocks this pathway. Although no
dominant–negative mutations have been reported in SMA
patients, possibly because they would result in embryonic
lethality, a point mutation in exon 1 has been identified in
three unrelated SMA patients (Parsons et al., 1998). This
suggests that the amino acid sequence encoded by exon 1,
which is deleted in SMNDN27, is important for SMN func-
tion and SMA. Moreover, we recently identified a domi-
nant-negative mutant of Gemin2 that displays a pheno-
type similar to SMNDN27 (Pellizzoni, L., and G. Dreyfuss,
manuscript in preparation). The observation that expres-
sion of mutants of two different proteins of the SMN com-
plex leads to the dramatic reorganization of components
of the pol II transcription/processing machinery, and the
inhibition of transcription in vivo argues that these effects
result from disruption of a genuine pathway that requires
SMN functions in normal cells.
Pol II CTD undergoes cycles of phosphorylation and de-
phosphorylation that modulate its association with pro-
cessing factors and its activity in transcription (Dhamus,
1996). Pol IIa binds to the preinitiation complex on pro-
moter elements, and CTD phosphorylation is believed to
trigger release from the promoter and initiation of tran-
scription (Lu et al., 1991; Akoulitchev et al., 1995). Pol IIo
drives elongation and pre-mRNA processing events and is
released from the gene upon termination of transcription
(O’Brien et al., 1994). After their release from sites of
transcription, pol II and several components of the tran-
scription and pre-mRNA processing machineries seem to
follow a common pathway in the nucleus (Zeng et al.,
1997). A pool of both pol II isoforms exists in the nucleo-
plasm that is not engaged in active transcription and may
represent the fraction of pol II undergoing recycling or re-
generation between rounds of transcription (Kim et al.,
1997; Zeng et al., 1997). Dephosphorylation of pol II CTD
is one of the steps required for pol II recycling (Cho et al.,
1999). The observation that the SMN complex associates
with both pol II isoforms but only pol IIa accumulates in
the G/CBs upon SMNDN27 expression, suggests that pol
II CTD dephosphorylation may take place in association
with components of the SMN complex and that SMNDN27
blocks the pathway downstream of this event.
HnRNP and SR proteins represent indirect markers of
pre-mRNA distribution in the nucleus, and these abun-
dant RNA-binding proteins do not accumulate in G/CBs
(Fig. 6). Moreover, hnRNP proteins do not coimmunopre-
cipitate with the SMN complex (Fig. 2; data not shown).
Figure 8. Expression of
SMNDN27 inhibits transcrip-
tion by RNA pol I and II in
vivo. (A–F) Double-label la-
ser confocal microscopy of
HeLa cells transiently trans-
fected with mycSMNwt (A–
C) and mycSMNDN27 (D–
F), showing the incorporation
of BrU into RNA by indirect
immunofluorescence using
anti-myc (A and D) and anti-
BrU (B and E) antibodies.
BrU incorporation was per-
formed as described in Mate-
rials and Methods on trans-
fected cells before fixation
and immunofluorescence
staining. The respective com-
bined images are shown in C
and F. Colocalization results
in a yellow signal. Dashed
lines demarcate the nucleus.
The nucleolus is indicated by
an arrow in E. Bar, 5 mm.The Journal of Cell Biology, Volume 152, 2001 84
These results suggest that the SMN complex associates
with transcriptosome components that are not bound to
pre-mRNAs. It is tempting to speculate that pol II and
transcriptosome components associate with the SMN com-
plex after their dissociation from transcribing genes and
before being recruited for a new round of transcription.
TBP is a general transcription factor common to all three
RNA polymerases (Hernandez, 1993; Rigby, 1993). TBP
accumulates in the G/CBs upon expression of SMNDN27,
and likely as a consequence pol I transcription in the nucle-
olus is strongly inhibited. Similar to the case of pol II, RNA
polymerase I holoenzyme as a transcriptionally competent
large multisubunit complex has been identified, and the
possibility that it may be preassembled in CBs has been sug-
gested (Seither et al., 1998; Gall et al., 1999). By extension
of what we have observed here for components of pol II
transcriptosomes, the SMN complex may interact with com-
ponents of the pol I transcription machinery and also play a
role in the assembly of a class I transcriptosome. Experi-
ments are underway to assess this possibility.
Our findings suggest a critical role for the SMN complex
in several aspects of mRNA biogenesis. Neurons are likely
to be particularly sensitive to defects in mRNA metabo-
lism as neuronal differentiation and maintenance require
highly active and finely regulated pre-mRNA transcrip-
tion and processing activities (Tanabe and Jessell, 1996;
Grabowski, 1998). It is conceivable that the drastic reduc-
tion in the amount of SMN in motor neurons of SMA pa-
tients leads to an impaired capacity to produce mRNAs,
and thus leads to neuronal degeneration.
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